Introduction
Adenosine signaling plays a complex role in multiple physiological and pathophysiological processes in the brain. Among the four known adenosine receptors, referred to as adenosine A 1 , A 2A , A 2B , and A 3 receptor [1] , the A 1 and A 2A receptors are abundantly and widely distributed in the human central nervous system [2] . All adenosine receptors belong to class A family of G-protein-coupled receptor (GPCR) superfamily, and it has been generally accepted that adenosine A 1 receptor is primarily coupled to Gi/o to inhibit adenylyl cyclase whereas adenosine A 2A receptor is mainly coupled to Gs to activate the enzyme activity. Agonist-stimulated guanosine-5′-O-(3-[ 
]GTPγS) binding assay has been widely used to assess functional activation of G-proteins, especially Gi/o proteins, coupled to multiple receptors [3, 4] . Adenosine A 1 receptor is one of these receptors, and functional activation of Gproteins coupled to adenosine A 1 receptor has been reported by [ 35 S]GTPγS binding in native bovine or rat brain membranes [5] [6] [7] and by [ 35 S]GTPγS autoradiography [7] [8] [9] . Although these methods have been widely utilized in neuroscience research to investigate receptor/G-protein interaction between inhibitory receptors and Gi/o proteins, it is not possible to differentiate each G-protein subtype functionally coupled to the receptor by using conventional [ ]GTPγS binding assay combined with immunoprecipitation using an anti-Gα subtype antibody [10] . By using this method, we have revealed that adenosine A 1 receptor is coupled preferentially to Gα i-3 in postmortem human prefrontal cortical membranes. Adenosine signaling dysfunction in the brain has been implicated in pathophysiology of neuropsychiatric diseases such as schizophrenia and affective disorders [11] [12] [13] [14] . However, direct studies on the adenosinergic system in mental disorders are strikingly scare, especially for adenosine A 1 receptor-mediated signaling. Based on these considerations, we have a plan to assess possible alterations in adenosine A 1 receptor-mediated G-protein activation in psychiatric disorder patients in comparison with control subjects. Ahead of this, the present study aimed at elucidating functional coupling between adenosine A 1 receptors and G-proteins in postmortem human brain membranes in a control cohort. In addition, several issues related to the methods of adenosine A 1 receptor-mediated G-protein activation have been addressed both in rat and postmortem human brain membranes. Since adenosine deaminase (ADA) is sometimes included routinely in the assay buffer to diminish the possible effects of residual endogenous adenosine in [ 35 S]GTPγS binding assay, especially in autoradiography studies [7, 8] , we have tried to elucidate to which extent the residual endogenous adenosine affects the basal and stimulated [ 35 Dynabeads Protein A was purchased from ThermoFisher Scientific (Waltham, MA, USA). The rabbit polyclonal antibodies to Gα subtypes (sc-391 for Gα i-1 , sc-7276 for Gα i-2 , sc-262 for Gα i-3 , and sc-387 for Gα o ) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Adenosine deaminase (ADA) from calf intestine and Nonidet P40 substitute were obtained from Roche Diagnostics GmbH (Mannheim, Germany). Other chemicals used in this study were of analytical grade.
S]GTPγS binding in these measurements.

Materials and methods
Chemicals and reagents
Animals
Male Sprague-Dawley rats weighing 200-250 g were purchased from Kiwa Laboratory Animals Co. (Wakayama, Japan) and housed in groups under controlled light and humidity conditions with free access to food and water for several days until sacrifice. The experimental protocols were reviewed and approved by the Animal Committee of Saitama Medical University, and the animal care and use procedures conformed to the European Community Guidelines for the use of Experimental Animals (86/609/EEC).
Postmortem human brains
Postmortem human brain samples were obtained at autopsy in the Basque Institute of Legal Medicine (Bilbao, Spain), in accordance with protocols approved by the Human Studies Ethical Committee of each of the institutions involved. Dorsolateral prefrontal cortices (Brodmann's area 9) dissected from 40 subjects (24 males and 16 females, aged from 16 to 80 years old) without known history of neurological or psychiatric disorders were used. The detailed information on these samples have been described elsewhere [15] .
Membrane preparation
Rats were sacrificed, and the cerebral cortex, hippocampus, and striatum were dissected quickly. Rat or human brain tissue was homogenized in 5 mL of ice-cold TED buffer (5 mM Tris-HCl, 1 mM EDTA, 1 mM dithiothreitol; pH 7.4) containing 10% (w/v) sucrose by 20 strokes with a motor-driven Teflon/glass tissue grinder. All of the following centrifuge procedures were performed at 4°C. Subsequent to centrifugation of the homogenate at 1000 g for 10 min, the supernatant was decanted to another centrifuge tube. The pellet was vortexed in 5 mL of TED/sucrose buffer and centrifuged again at 1000g for 10 min. The combined supernatant (10 mL) was centrifuged at 9000g for 20 min and resuspended in 10 mL of TED buffer. After the same procedure was repeated, the homogenate was kept on ice for 30 min, followed by a final centrifugation at 35,000g for 10 min. The resulting pellet was resuspended in 50 mM Tris-HCl buffer (pH 7.4) to produce the homogenate with a protein concentration of 1.0-2.0 and 2.0-3.0 mg/mL for rat and human brain, respectively. The homogenate was frozen quickly on fine-grained dry ice and stored at − 80°C until the day of experiment.
Conventional [
S]GTPγS binding assay
The [
35 S]GTPγS binding assay using filtration techniques were performed according to the methods described previously [16] . In brief, brain membranes equivalent to 10-20 μg protein (rat) or 60 μg protein (human) were incubated in duplicate at 30°C for 60 min in 500 μL of 50 mM Tris-HCl buffer (pH 7.4) containing 0.2 nM [
35 S]GTPγS, 5 mM MgCl 2 , 0.1 mM ethylenediaminetetraacetic acid, 0.2 mM ethylene glycolbis(2-aminoethylether)-N,N,N,N-tetraacetic acid (EGTA), 0.2 mM dithiothreitol, 100 mM NaCl, 20 μM (rat) or 50 μM (human) GDP, and the compound of interest at the indicated concentration. After the incubation, the homogenate was filtered under vacuum through glass fiber filters (GF/B; Whatman International, Maidstone, UK) using a Brandel cell harvester with 2 × 5 mL washing with ice-cold 50 mM TrisHCl buffer (pH 7.4). The nonspecific binding was measured in the presence of 100 μM unlabeled GTPγS.
[ 35 
S]GTPγS binding/immunoprecipitation assay
The [ 35 S]GTPγS binding/immunoprecipitation assay was performed according to the methods described previously [10, 16] . The brain membranes were diluted with 50 mM TrisHCl buffer (pH 7.4) to contain 20 μg protein (rat) or 80 μg protein (human) in 100 μL and were incubated with the compound of interest diluted in 50 μL distilled water at room temperature for 30 min in 1.5 mL polypropylene microtube. Subsequent to the addition of 50 μL assay mixture, the incubation was performed for 60 min in 200 μL of 50 mM TrisHCl buffer (pH 7.4) containing 2 nM [ 
Determination of adenosine content
Adenosine content in membrane preparation was examined after acid extraction and converting to fluorescent derivative 1,N 6 -etheno adenosine. Washed membrane preparation was adjusted to 1 mg protein/mL, and aliquots (100 μL) were mixed with 100 μL of 5% HClO 4 for measuring total adenosine content in membrane preparation. To determine whether adenosine release from membrane vesicle to incubation medium during biding experiments, aliquots (150 μL) of membrane fraction were incubated for 30 min at 30°C, followed by centrifuging at 21,500g for 10 min at 4°C. The supernatant was mixed with equal volume of 5% HClO 4. Acid extracts of membrane and incubated medium were mixed with 1/10 vol. of 4.2 M KOH to neutralize and deposit potassium perchlorate. Adenosine in the acid extracts were converted to 1,N 6 -etheno derivatives by treating with 1% chloroacetaldehyde at 80°C for 30 min [17] . The 1,N 6 -etheno adenine nucleotides were separated using a JASCO HPLC system equipped with an analytical YMC-Pack ODS-A column (S-5, 4.6 × 100 mm, YMC Inc., Kyoto, Japan) [18] and monitored by a fluorescence detection following excitation at 270 nm at the emission wavelength of 410 nm.
Data analysis
The concentration-dependent increase in the specific [ 35 S]GTPγS binding by adenosine was expressed as % over the basal unstimulated binding and analyzed by means of a non-linear regression method using GraphPad Prism (GraphPad Software; La Jolla, CA, USA), to produce the concentration eliciting the half-maximal effect (EC 50 ) and the maximal of percent increase (%E max ). The concentrationresponse curves for the compounds depicted in Fig. 1 were analyzed, with the stimulatory effect elicited by 100 μM adenosine determined in the same experiment assumed as 100%. The inhibitory effects of adenosine antagonists on the basal binding were also analyzed by a non-linear regression method, with the basal binding regarded as 100%. Results were presented as the mean ± S.E. 50 , %E max , and slope factor) determined by the two methods in human brain samples.
Results
Pharmacological characterization of adenosine-induced [ Fig. 1 ). The maximal increases by these three compounds were 90-100% of the value determined in the presence of 100 μM adenosine. On the other hand, the selective adenosine A 2A receptor agonist CGS21680 had a stimulatory effects only at the concentrations of micromolar range, resulting in a mean EC 50 value of 15 μM (pEC 50 = 4.82 ± 0.12). The maximal increase was 83.2 ± 8.7% (N = 3) of the value determined in the presence of 100 μM adenosine.
In postmortem human prefrontal cortical membranes, the effects of PSB36, a selective adenosine A 1 receptor antagonist [20] , on adenosine-induced [ Identification of Gα subtype coupled to adenosine A 1 receptor determined by [ 35 
S]GTPγS binding/immunoprecipitation assay in rat brain membranes
In our previous study on the [ 35 S]GTPγS binding/ immunoprecipitation assay, it was shown that adenosine A 1 receptor was selectively coupled to Gα i-3 in postmortem human brain membranes [10] . However, species differences in the G-protein selectivity for adenosine A 1 receptor have been demonstrated [21] . With possible species differences in mind, adenosine-induced G-protein activation was investigated In the experiments for the agonists except for adenosine, the binding in the presence of 100 μM adenosine was also determined, which was regarded as a maximal stimulation using several specific anti-Gα subtype antibodies in rat brain membranes. Since the preliminary experiments (N = 3) demonstrated that the increase in specific [ 35 
S]GTPγS binding to
Gα i-3 elicited by 1 mM adenosine was highest in the cerebral cortex (226 ± 18% basal) and then in the striatum (197 ± 24% basal), but only slight in the hippocampus (118 ± 18% basal), the former two brain regions were further investigated. Oneway ANOVA indicated statistically significant effects in rat cerebral cortex [F(4,20) = 14.65, P < 0.0001] as well as in striatum F(4,10) = 49.99, P < 0.0001]. Among Gα subtypes, a significant increase elicited by 1 mM adenosine was obtained only for Gα i-3 (P < 0.001, Tukey's post hoc test) but not for other Gα i/o subtypes, in both brain regions (Fig. 3) .
Effects of adenosine receptor antagonists on basal [ 35 S]GTPγS binding to Gα i/o
In rat cerebral cortical membranes, the basal specific 
Effects of adenosine receptor antagonists on basal [ 35 S]GTPγS binding to Gα i-3
The inhibitory effects of several adenosine receptor antagonists on the basal specific [ 
Concentrations of adenosine in membrane preparation and supernatant
Concentrations of adenosine, determined after extraction from the brain membrane preparations adjusted to 1 mg protein/mL, were within a range of 1-2 μM, for all three rat brain regions as well as for postmortem human prefrontal cortex ( Table 1 ).
The adenosine concentrations were also determined in supernatant fractions after incubation of the brain membrane preparations at 30°C for 30 min. In the case of rat brain membranes, the concentrations of adenosine in supernatant were 350 ± 70, 191 ± 15, and 233 ± 40 nM, in the cerebral cortex, hippocampus, and striatum, respectively. Conversely, the supernatant fraction of postmortem human prefrontal cortical membranes contained only one-tenth of the levels found in rat brain membranes (28 ± 6 nM).
Effects of ADA on [ 35 
S]GTPγS binding to Gα i/o
The effects of ADA on the basal specific [ (Fig. 6a) . In the presence of ADA at 20 U/tube, the basal binding was inhibited to 55.3 ± 2.4% (N = 4) of the binding determined in the absence of ADA. The similar inhibitory effects were also observed in hippocampal and striatal membranes, though to a somewhat smaller extent [72.9 ± 3.9% (N = 3) and 67.2 ± 3.6% (N = 3) in the presence of 20 U/tube ADA in the hippocampus and striatum, respectively] (not shown). In order to ascertain that the influence of ADA derived from its enzymatic activity, we tried to verify whether pretreatment of ADA by heating abolished its inhibitory effects. The enzymatic inactivation of ADA by heating did not reverse the inhibitory effects of ADA, contrary to expectation (Fig. 6a, inset) .
In postmortem human prefrontal cortical membranes, ADA inhibited the basal specific [
35 S]GTPγS binding to Gα i/o (Fig. 6b) . The inhibitory effects of ADA were observed at very low concentrations as compared to those in rat brain membranes. Thus, in the presence of ADA at 1 mU/tube, the basal binding was inhibited to 82.4 ± 2.4% (N = 4). This inhibitory effect of ADA was canceled when ADA was inactivated by boiling (95°C for 5 min) beforehand (Fig. 6b, inset) .
Effects of ADA on [ In rat cerebral cortical membranes, the effects of ADA appeared inconsistent (Fig. 7a) . The inhibitory effects of ADA were observed in some experiments, whereas ambiguous or even stimulatory effects were detected in other experiments. In the rat brain membranes in which the stimulatory effects of ADA were observed, these effects were not altered by the pretreatment of ADA by heating (not shown).
In postmortem prefrontal cortical membranes, the basal specific [
35 S]GTPγS binding to Gα i-3 was inhibited by ADA in a concentration-dependent manner (Fig. 7b) . In the presence of ADA at 5 U/tube, the basal binding was inhibited to 66.0 ± 2.1% (N = 4).
Effects of adenosine on [
S]GTPγS binding to Gα i/o in postmortem human brain membranes
As shown in Fig. 8 (Fig. 9) . The specific [ (Fig. 10a) . The significant positive correlation was kept in male subjects (r = 0.54, p < 0.05), but not in females. Another one was a significant correlation between postmortem delay and %E max values in adenosine-induced [ (Fig. 10b) . The correlation was still significant in the male subjects (r = 0.43, p < 0.05), but not in the female group.
Interrelation between adenosine-stimulated [ 
Discussion
In the present study, we utilized two [ 35 [19] , at submicromolar concentrations. The results depicted in Fig. 1 indicate that all of these three compounds behave as almost full agonists, with intrinsic activities of 90-100%. Although it is exceedingly difficult to determine the affinity of the endogenous ligand adenosine to adenosine receptors [19] , one study using a functional assay for inhibitory effects on adenylate cyclase in rat fat cell membranes has indicated that its potency to adenosine A 1 receptor is 73 nM [22] . Also, it was reported that adenosine inhibited forskolin-stimulated cyclic AMP formation in Chinese hamster ovary (CHO) cells stably transfected with human adenosine A 1 receptor with an EC 50 of 310 and 54 nM in the absence and presence of nitrobenzylthioinosine (adenosine transport inhibitor), respectively [23] . The stimulatory effects of CGS21680, a selective adenosine A 2A receptor agonist, at higher concentrations are likely attributable to its property as a weak agonist at adenosine A 1 receptor [24] [25] [26] . The intrinsic activity of CGS21680 (83.2 ± 8.7%) appeared somewhat lower than other three compounds. However, the exact intrinsic activity of this compound is difficult to determine due to a lack of enough saturability at the concentrations investigated in the present study. According to the previous report [25] , CGS21680 has been reported to act as a full agonist at human adenosine A 1 receptor expressed in CHO cells. In postmortem human prefrontal cortical membranes, adenosinestimulated [ [20] .
Differences in G-protein coupling with adenosine A 1 receptors from rat, human, and bovine brain have been demonstrated [21, 27] . In the present study, we verified whether selective coupling between adenosine A 1 receptor and Gα i-3 observed in postmortem human brain membranes [10] was also detected in rat brain membranes. As in human brain membranes, adenosine-induced [ [2, 28, 29] . Although an immunohistochemical study indicates the existence of Gα i-3 -peptidepositive neurons in the hippocampus [30] , the expression level of Gα i-3 proteins may be lower in hippocampus than in other brain regions such as the cerebral cortex and striatum. Alternatively, coupling efficiency between adenosine A 1 receptor and Gα i-3 protein may be weak in the hippocampus compared to the two other brain regions.
Several adenosine receptor antagonists inhibited the basal [ Since it has been shown that some adenosinergic ligands including DPCPX act as an inverse agonist, but not as a neutral antagonist [31] , it is possible to regard the data obtained in the present study as the effects of inverse agonists on constitutive active adenosine A 1 receptors in the brain membranes. However, since the constitutive activity is mainly evidenced for recombinant receptors overexpressed and/or mutated [32, 33] , an alternative explanation for the phenomena is that the negative intrinsic activities of these compounds derive from pseudo basal binding levels due to the presence of residual endogenous adenosine in the assay buffer [7, 34] . In either way, the rank order of potencies of these antagonists in rat cerebral cortical membranes, i.e., DPCPX >> 1,3-dimethyl-8-phenylxanthine > VUF5574 > theophylline > caffeine, indicates the involvement of adenosine A 1 receptor subtype [19, 35] . Similar inhibition of the basal [ The question of whether residual endogenous adenosine exists in incubation buffer under the experimental conditions in the present study was addressed by direct determination of adenosine concentrations. The results indicate that the membrane preparations used in the present study contain substantial contents of adenosine. Moreover, endogenous adenosine is detectable in the supernatant fraction (350 and 28 nM in rat and human cortex, respectively) subsequent to the incubation of the membranes (1 mg protein/mL). If it is assumed that the rate of endogenous adenosine production by membranes is proportional to the concentration of membrane protein, it follows that the assay buffer in the conventional [ 35 S]GTPγS binding experiments using rat (10-20 μg protein/500 μL) and human (60 μg protein/500 μL) cortical membranes contains 7-14 and 3 nM adenosine, respectively. In the [
35 S]GTPγS binding/ immunoprecipitation study, the assay was performed with the membranes prepared from rat (20 μg protein/200 μL) and human (80 μg protein/200 μL), and adenosine concentration in the assay buffer was calculated to be 35 and 11 nM, respectively. These concentrations of endogenous adenosine are very low as compared with the EC 50 values of adenosine, and thus, it is unlikely that the basal [ 35 S]GTPγS binding is elevated to a considerable extent by the existence of residual adenosine in the experimental conditions adopted in the present study.
Although ADA has been included in experimental systems frequently in order to remove endogenous adenosine in radioligand binding and functional assays for adenosine receptors, little information is available as to how much ADA is necessary and enough [34] . In the present study, the results indicate that ADA affects the basal [ ]GTPγS binding to Gα i-3 were inhibitory as anticipated in some samples, but even stimulatory in others. These stimulatory effects of ADA appear to be irrelevant to its activity as an enzyme, because the pretreatment of ADA by heating failed to counteract its effects (not shown).
All of the abovementioned results, i.e., decrease in basal ]GTPγS binding/immunoprecipitation assay in rat brain membranes prompted us to hesitate to include ADA routinely in assay buffers. It has been reported that ADA is a moonlighting protein, with multifunctional properties (e.g., as an allosteric modulator of adenosine receptors) in addition to its enzymatic activity [37] . The perplexing results of ADA in the present study may be ascribed to its functions other than catalytic action. Moreover, the presumed concentrations of adenosine in incubation mixture in the present study are only nanomolar order, much lower in comparison with the reported potencies of adenosine at adenosine A 1 receptor [22, 23] and with the EC 50 values determined in the present study (200 and 450 nM in rat and human brain membranes, respectively, in conventional [ 35 S]GTPγS binding assay; 820 nM in h u m a n m e m b r a n e s i n [ 3 5 S ] G T P γ S b i n d i n g / immunoprecipitation assay). [10] , adenosine-stimulated G-protein activation was determined in prefrontal cortical membranes prepared from 40 subjects with no psychiatric and/or neurological disorders (16~80 years old). There have been lots of reports dealing with alterations in the number of adenosine A 1 receptors according to aging. Most of such studies using radioligand binding assay or quantitative autoradiography in rodent brains [38] [39] [40] [41] [42] as well as positron emission tomography (PET) in living humans [43, 44] have indicated consistently agerelated decline of adenosine A 1 receptors in the brain. However, conflicting results as to the declining effects of aging on adenosine A 1 receptor density have also been reported by several studies [28, [45] [46] [47] [48] [49] [50] . Ułas et al. [51] demonstrated that coupling of adenosine A 1 receptors to G-proteins remained unaltered in spite of remarkable reduction of their density in hippocampus of patients with Alzheimer's disease. Even if there may be a tendency of age-dependent reduction of adenosine A 1 receptors, the coupling efficiency between adenosine A 1 receptors and G-proteins is enhanced, rather than reduced, according to aging, likely by compensatory mechanisms.
The %E max values of adenosine-stimulated [ [53] [54] [55] [56] [57] [58] , this rule is not generalized to all receptors. Indeed, the unaltered or even increased receptor binding induced by postmortem delay has been reported for some receptors [54] [55] [56] . Since the information on how postmortem delay affects adenosine A 1 receptor binding is unavailable, it is unknown whether the results obtained in the present study are attributable to increase in adenosine A 1 receptors or to strengthened coupling efficiency between adenosine A 1 receptor and G-protein by prolonged postmortem period.
A lack of correlation between parameters such as %E max values of adenosine-stimulated [ Nevertheless, the varied patterns of ADA discouraged us from adding ADA into assay medium routinely. The concentration-dependent increases elicited by adenosine were determined in 40 subjects without any neuropsychiatric disorders. The increases in %E max values determined by conventional assay according to aging and postmortem delay should be taken into account in future studies focusing on the effects of psychiatric disorders on adenosine A 1 receptor/ G-protein interaction in postmortem human brain tissue. Ethical approval All animals received care according to institutional guidelines, and all procedures were according to the European Community Guidelines for the use of Experimental Animals (86/609/ EEC) after approval by the Animal Committee of Saitama Medical University. All procedures regarding postmortem human brains were in accordance with protocols approved by the Human Studies Ethical Committee of each of the institutions involved.
